Glioblastoma Multiforme Treatment Drugs Market is Anticipated to Increase at a Stable CAGR over the Forecast Period (2023 to 2029)
The increasing approval for novel therapy and combination therapy is expected to drive the market in the coming years. For instance, in June 2019, the U.S. FDA approved Pfizer's Zirabev, a biosimilar for Avastin, for the treatment of recurrent glioblastoma, NSCLC, and colorectal cancer, among others. In January 2020, the company launched its product in the U.S.
The global glioblastoma multiforme treatment drugs market analysis includes some of the key market players such as Sanofi S.A., Eli Lilly and Company, AstraZeneca plc., Astellas Pharma Inc., and Johnson & Johnson (Janss en Pharmaceuticals), among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in November 2019, the U.S. FDA accepted Samsung's BLA application for its SB8 bevacizumab biosimilar candidate, which will increase the potential to launch products in the coming years.
To Request a Sample of our Report on Glioblastoma Multiforme Treatment Drugs Market: https://www.omrglobal.com/request-sample/glioblastoma-multiforme-treatment-drugs-market
· The market number available for - 2021-2029
· Base year- 2021
· Forecast period- 2023-2029
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Bausch Health Companies Inc., Nestlé (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris Therapeutics, among others.
Glioblastoma Multiforme Treatment Drugs Market by Segment
• Radiation Therapy
By Drug Class
• Ambulatory Surgical Centers
A full Report of Glioblastoma Multiforme Treatment Drugs Market is Available at: https://www.omrglobal.com/industry-reports/glioblastoma-multiforme-treatment-drugs-market
Glioblastoma Multiforme Treatment Drugs Market by Region
· United States
· Rest of Europe
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Contact no: +91 7803040404
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme Treatment Drugs Market is Anticipated to Increase at a Stable CAGR over the Forecast Period (2023 to 2029) here
News-ID: 2963830 • Views: 312
More Releases from Orion Market Research
US Consumer Packaging Market Booming Worldwide with Latest Trend and Future Scop …
The US consumer packaging market is estimated to grow at a CAGR of 4.5% during the forecast period. Rising demand for flexible packaging across end-user industries is primarily leveraging market growth. As per the Flexible Packaging Association (FPA), in the US, the flexible packaging industry generated $31.8 billion in sales in 2018. It is the second-largest packaging segment in the country accounted for nearly 19% of the $170 billion US
North American Consumer Packaging Market Will Generate Record Revenue by 2029
North American consumer packaging market is estimated to grow at a CAGR of 3.8% during the forecast period. North American is the leader in the pharmaceutical industry, coupled with the presence of several large and small pharmaceutical firms in the region. The region is renowned for conducting massive R&D and produce bulk pharmaceuticals. As per the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2017, North American held 48.1%
European Consumer Packaging Market Comprehensive Insight by Growth Rate, Industr …
The European consumer packaging market is estimated to grow at a CAGR of 4.8% during the forecast period. Significant rise in the packaging industry and increasing pharmaceutical production are some key factors primarily contributing to market growth. As per the PlasticsEurope, in 2018, the European plastics industry generated revenue of over $413.3 billion, with a positive trade balance of over $17.2 billion. In 2018, 9.4 million tons of plastic post-consumer
Asia-Pacific Consumer Packaging Market is Anticipated to Increase at a Stable CA …
Asia-Pacific consumer packaging market is estimated to grow at a significant CAGR of 7.0% during the forecast period. The major factors contributing to the growth of the market include a significant rise in the production of food and beverage and pharmaceuticals in the region. The rising demand for processed food is one of the major causes that accelerates the demand for packaging solutions in the region. As per the India
More Releases for Glioblastoma
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. Request Sample Report: https://precisionbusinessinsights.com/request-sample?product_id=16248 The global glioblastoma multiforme treatment market is
Glioblastoma Treatment Drugs Market : Drivers, Restraint & Future Growth
Brain tumors is one of the leading cause of cancer which is common among children and teenagers. Glioblastoma (GBM) is most common grade four tumor, is malignant and contains dead tumor cells. It is also called as Glioblastoma multiforme, it has variants of giant cell Glioblastoma and gliosarcoma found in cerebral hemisphere of brain. The exact cause of this tumor is not known but is also found in spinal cord
Glioblastoma Multiforme Treatment Market : Global Glioblastoma Multiforme Treatm …
Glioblastoma Multiforme Treatment Market Precision Business Insights (PBI) in its report titled “Global Glioblastoma Multiforme Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Glioblastoma multiforme is the high-grade glioma and
Glioblastoma Multiforme Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape. Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging